Open access · CC-BY
via OpenAlex
Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors
Carolina Becker Livi, Rulon L. Hardman, Barbara A. Christy, Sherry G. Dodds, Diane Jones, Charnae E. Williams, Randy Strong, Alex F. Bokov, Martin A. Javors, Yuji Ikeno, Gene B. Hubbard, Paul Hasty, Zelton Dave Sharp
Aging · 2013 · ▲ 86 citations
Abstract
Chronic treatment of mice with an enterically released formulation of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of thesein vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1+/- mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1+/- mice, suggesting that the beneficial response to DR is dependent on pRb1. Since long-term eRapa treatment may at least partially mimic chronic DR in lifespan extension, we predicted that it would have a minimal effect in Rb1+/- mice. Beginning at 9 weeks of age until death, we fed Rb1+/- mice a diet without or with eRapa at 14 mg/kg food, which results in an approximate dose of 2.24 mg/kg body weight per day, and yielded rapamycin blood levels of about 4 ng/ml. Surprisingly, we found that eRapa dramatically extended life span of both female and male Rb1+/- mice, and slowed the appearance and growth of pituitary and decreased the incidence of thyroid tumors commonly observed in these mice. In this model, eRapa appears to act differently than DR, suggesting diverse mechanisms of action on survival and anti-tumor effects. In particular the beneficial effects of rapamycin did not depend on the dose of Rb1.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.100533
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Livi, C.B., Hardman, R.L., Christy, B.A., Dodds, S.G., Jones, D., Williams, C.E., Strong, R., Bokov, A.F., Javors, M.A., Ikeno, Y., Hubbard, G.B., Hasty, P., & Sharp, Z.D. (2013). Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors. <em>Aging</em>. https://doi.org/10.18632/aging.100533
Vancouver
Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams CE, et al. Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors. Aging. 2013. doi:10.18632/aging.100533.
BibTeX
@article{carolina2013Rapamy,
title = {Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors},
author = {Carolina Becker Livi and Rulon L. Hardman and Barbara A. Christy and Sherry G. Dodds and Diane Jones and Charnae E. Williams and Randy Strong and Alex F. Bokov and Martin A. Javors and Yuji Ikeno and Gene B. Hubbard and Paul Hasty and Zelton Dave Sharp},
journal = {Aging},
year = {2013},
doi = {10.18632/aging.100533},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2015
Open access · CC-BY
Sex‐ and tissue‐specific changes in mTOR signaling with age in C57 BL /6J mice
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · CC-BY
Rapamycin treatment during development extends lifespan and healthspan
The Journals of Gerontology Series A 2010
Open access · OA
Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
bioRxiv (Cold Spring Harbor Laboratory) 2020
Preprint · CC-BY
The Effect of a Ketogenic Diet and Synergy with Rapamycin in a Mouse Model of Breast Cancer
Innovation in Aging 2019
Open access · CC-BY
MACHINE LEARNING ANALYSIS OF MOUSE FRAILTY FOR PREDICTION OF BIOLOGICAL AGE AND LIFE EXPECTANCY
The Journals of Gerontology Series A 2010
Open access · OA